News >

FDA Grants Priority Review to Nivolumab/Ipilimumab in Advanced HCC

Gina Columbus
Published: Monday, Nov 11, 2019

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with advanced hepatocellular carcinoma (HCC) who received prior therapy with sorafenib (Nexavar).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication